Medicxi Raises $400M for Asset-Centric Biotech Investing

Medicxi, a biotech investment firm, raises $400M to fuel its asset-centric investment strategy, focusing on building new companies around specific experimental products. This approach aims to support promising biotechs regardless of their development stage, especially during market tightness. The fundraise comes amidst a surge in biotech venture funding, driven by lower interest rates and fresh investor cash. Medicxi has seen significant success, realizing over $1B in returns across its portfolio, with companies like Merus and ProfoundBio being acquired in large deals.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.